The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type IIIL-1 receptor to inhibit IL-1 action

被引:150
作者
Smith, DE
Hanna, R
Friend, D
Moore, H
Chen, H
Farese, AM
MacVittie, TJ
Virca, GD
Sims, JE
机构
[1] Amgen Corp, Seattle, WA 98101 USA
[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
关键词
D O I
10.1016/S1074-7613(02)00514-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Regulation of the activity of the proinflammatory cytokine IL-1 is complex, involving transcriptional and translational control, precursor processing, a receptor antagonist (IL-1ra), and a decoy receptor. Here we report that the soluble form of the IL-1 receptor accessory protein (AcP) increases the affinity of binding of human IL-1alpha and IL-1beta to the soluble human type 11 IL-1 receptor by approximately 100-fold, while leaving unaltered the low binding affinity of IL-1ra. Soluble AcP is present in normal human serum at an average concentration greater than 300 ng/ml. These findings suggest that the soluble form of IL-1 R AcP contributes to the antagonism of IL-1 action by the type 11 decoy receptor, adding another layer of complexity to the regulation of IL-1 action.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 25 条
[1]   MOLECULAR CHARACTERIZATION OF MURINE AND HUMAN OX40/OX40 LIGAND SYSTEMS - IDENTIFICATION OF A HUMAN OX40 LIGAND AS THE HTLV-1-REGULATED PROTEIN GP34 [J].
BAUM, PR ;
GAYLE, RB ;
RAMSDELL, F ;
SRINIVASAN, S ;
SORENSEN, RA ;
WATSON, ML ;
SELDIN, MF ;
BAKER, E ;
SUTHERLAND, GR ;
CLIFFORD, KN ;
ALDERSON, MR ;
GOODWIN, RG ;
FANSLOW, WC .
EMBO JOURNAL, 1994, 13 (17) :3992-4001
[2]   THE INHIBITORY ACTIVITY OF HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IS ENHANCED BY TYPE-II INTERLEUKIN-1 SOLUBLE RECEPTOR AND HINDERED BY TYPE-I INTERLEUKIN-1 SOLUBLE RECEPTOR [J].
BURGER, D ;
CHICHEPORTICHE, R ;
GIRI, JG ;
DAYER, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :38-41
[3]   INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4 [J].
COLOTTA, F ;
RE, F ;
MUZIO, M ;
BERTINI, R ;
POLENTARUTTI, N ;
SIRONI, M ;
GIRI, JG ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
SCIENCE, 1993, 261 (5120) :472-475
[4]   Anti-interleukin-1 therapy in rheumatic diseases [J].
Dayer, JM ;
Feige, U ;
Edwards, CK ;
Burger, D .
CURRENT OPINION IN RHEUMATOLOGY, 2001, 13 (03) :170-176
[5]  
Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005
[6]   PREVENTION OF COLLAGEN-INDUCED ARTHRITIS WITH AN ANTIBODY TO GP39, THE LIGAND FOR CD40 [J].
DURIE, FH ;
FAVA, RA ;
FOY, TM ;
ARUFFO, A ;
LEDBETTER, JA ;
NOELLE, RJ .
SCIENCE, 1993, 261 (5126) :1328-1330
[7]  
EASTGATE JA, 1988, LANCET, V2, P706
[8]   PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION FROM COMPLEMENTARY-DNA OF A HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
EISENBERG, SP ;
EVANS, RJ ;
AREND, WP ;
VERDERBER, E ;
BREWER, MT ;
HANNUM, CH ;
THOMPSON, RC .
NATURE, 1990, 343 (6256) :341-346
[9]  
GIRI JG, 1994, J IMMUNOL, V153, P5802
[10]   MOLECULAR-CLONING AND CHARACTERIZATION OF A 2ND SUBUNIT OF THE INTERLEUKIN-1 RECEPTOR COMPLEX [J].
GREENFEDER, SA ;
NUNES, P ;
KWEE, L ;
LABOW, M ;
CHIZZONITE, PA ;
JU, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (23) :13757-13765